We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > RSV

News List

Suptavumab Does Not Meet Primary Endpoint americanpharmaceuticalreview
August 15, 2017
Regeneron Pharmaceuticals announced a Phase 3 study evaluating suptavumab (REGN2222), an antibody to respiratory syncytial virus (RSV), did not meet its primary endpoint of preventing medically-attended RSV infections in infants.
Sanofi Pasteur and MedImmune Collaborate on Monoclonal Antibody to Prevent Illnesses Associated with americanpharmaceuticalreview
March 06, 2017
Sanofi and its vaccines global business unit Sanofi Pasteur announced an agreement with MedImmune, the global biologics research and development arm of AstraZeneca,
Arsanis and Adimab Enter Into License Agreement to Target Respiratory Syncytial Virus (RSV) With Mon americanpharmaceuticalreview
February 28, 2017
Arsanis, Inc., a clinical-stage biopharmaceutical company developing targeted monoclonal antibodies for pre-emptive and post-infection treatment of serious infectious diseases,
Updated Phase I Data show Bavarian Nordic's vaccine candidate induces broad and durable immune respo cphi-online
February 27, 2017
Antibody levels maintained against multiple targets 6 months post vaccination.

Previous page 1 2 3 4 Next page